Early Response Indicators: Early reductions in fasting serum glucose [8] and body weight with tirzepatide were associated with better long-term metabolic outcomes, suggesting that early response may inform treatment individualization
When both operate simultaneously, you get appetite suppression from two independent mechanisms, enhanced fat oxidation from ketosis, improved insulin sensitivity from both pathways, and potentially better preservation of lean mass compared to either intervention alone
Hypersensitivity Reactions Inform patients that serious hypersensitivity reactions (e.g., urticaria, anaphylactic reactions, and angioedema) have been reported with the components of XIGDUO XR
Expanding indications for incretin-based therapies may amplify these concerns, as premature discontinuation often results in significant weight regain, likely reflecting the composition lost during clinical trials
Expected availability includes LillyDirect starting April 6 and later through retail pharmacies
